Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| RAD-140 (Testolone) | SR-9009 (Stenabolic) | |
|---|---|---|
| Category | SARMs | SARMs |
| Standard Dose | Research indicates 10-20 mg daily orally for 8-12 weeks. Phase 1 clinical trial (oncology) identified 100 mg as the maximum tolerated dose. | Research indicates 20-30 mg daily orally, split into 3-4 doses due to very short half-life (~4 hours). Some users prefer sublingual administration for improved bioavailability. |
| Timing | Once daily, consistent timing. Very long half-life (~60 hours) means stable plasma levels even with once-daily dosing. Morning preferred. | Split into 3-4 doses throughout the day due to ~4-hour half-life. Example: 7am, 11am, 3pm, 7pm. Avoid late-night dosing as REV-ERB modulation may affect circadian rhythm and sleep. |
| Cycle Duration | 8-12 week cycles. PCT mandatory due to significant HPG axis suppression. | 8-12 week cycles. No HPG suppression. Cycling recommended due to limited long-term data. |
| Evidence Level | animal_plus_anecdotal | animal_plus_anecdotal |
RAD-140 is a potent nonsteroidal SARM with high oral bioavailability and selectivity for muscle and bone AR over prostate. It acts as a full agonist at the AR in muscle tissue, promoting nitrogen retention and protein synthesis via mTOR/p70S6K pathway activation. RAD-140 also demonstrates neuroprotective properties, acting against beta-amyloid-induced neurotoxicity through AR-mediated MAPK/ERK signaling. Preclinical data show greater anabolic potency than testosterone propionate at equivalent doses with significantly reduced prostate stimulation.
Research indicates 10-20 mg daily orally for 8-12 weeks. Phase 1 clinical trial (oncology) identified 100 mg as the maximum tolerated dose.
Once daily, consistent timing. Very long half-life (~60 hours) means stable plasma levels even with once-daily dosing. Morning preferred.
8-12 week cycles. PCT mandatory due to significant HPG axis suppression.
SR-9009 is a synthetic agonist of REV-ERBa and REV-ERBb, nuclear receptors that form the repressive limb of the circadian clock and regulate metabolic gene expression. REV-ERB activation represses BMAL1/CLOCK transcription, modulating circadian rhythm. In skeletal muscle, SR-9009 increases mitochondrial count and oxidative capacity by upregulating mitochondrial biogenesis genes. It enhances fatty acid and glucose oxidation, increases exercise endurance, and reduces lipogenesis in the liver. SR-9009 also reduces inflammatory gene expression via NF-kB pathway suppression. Recent research has identified significant REV-ERB-independent effects, suggesting the mechanism is more complex than initially characterized.
Research indicates 20-30 mg daily orally, split into 3-4 doses due to very short half-life (~4 hours). Some users prefer sublingual administration for improved bioavailability.
Split into 3-4 doses throughout the day due to ~4-hour half-life. Example: 7am, 11am, 3pm, 7pm. Avoid late-night dosing as REV-ERB modulation may affect circadian rhythm and sleep.
8-12 week cycles. No HPG suppression. Cycling recommended due to limited long-term data.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →